22,371 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 22,371 shares of the medical equipment provider's stock, valued at approximately $1,926,000.

Other institutional investors also recently bought and sold shares of the company. DV Equities LLC bought a new position in Zimmer Biomet in the 4th quarter valued at $25,000. Tacita Capital Inc bought a new stake in shares of Zimmer Biomet during the second quarter worth $26,000. Monetary Solutions Ltd bought a new stake in shares of Zimmer Biomet during the fourth quarter worth $30,000. Gen Wealth Partners Inc purchased a new stake in shares of Zimmer Biomet during the fourth quarter valued at $31,000. Finally, Elevation Wealth Partners LLC boosted its stake in shares of Zimmer Biomet by 145.9% during the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 229 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Trading Up 2.1%

NYSE ZBH opened at $101.01 on Friday. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $108.29. The company has a 50 day moving average price of $92.64 and a 200 day moving average price of $91.00. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The firm has a market cap of $19.27 billion, a PE ratio of 24.58, a price-to-earnings-growth ratio of 2.75 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts' consensus estimates of $2.01 by $0.06. The company had revenue of $2.18 billion during the quarter, compared to analysts' expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The firm's revenue was up 4.8% compared to the same quarter last year. During the same period last year, the business posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Sang Yi sold 5,000 shares of the firm's stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.28% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on ZBH shares. Wells Fargo & Company dropped their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 29th. Zacks Research downgraded shares of Zimmer Biomet from a "hold" rating to a "strong sell" rating in a research note on Monday, July 27th. BMO Capital Markets reiterated a "market perform" rating and issued a $96.00 price target on shares of Zimmer Biomet in a report on Thursday, August 6th. Citizens Jmp dropped their price objective on Zimmer Biomet from $120.00 to $105.00 and set a "market outperform" rating on the stock in a research note on Wednesday, April 29th. Finally, Weiss Ratings upgraded Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $104.42.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source